CRISPR Therapeutics' stock faces challenges with slow Casgevy adoption and competition. See how CRSP stock remains a cautious ...

The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech won approval for its ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

The FDA has lost no time in approving Vertex Pharma and CRISPR Therapeutics pioneering gene-editing therapy Casgevy for its second use, approving the drug for transfusion-dependent beta ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Last month, the NICE endorsed Casgevy for use in the NHS under a managed access scheme to treat sickle cell disease.

With Casgevy’s buildup, two new drugs launching in 2025 and three others likely to complete Phase-III trials in 2026, further growth is likely over the next few years. Vertex has a market value ...

Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...

Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.

In the year-ago period, CRISPR Therapeutics received a major milestone payment from partner Vertex Pharmaceuticals VRTX in connection with the approval of one-shot gene therapy Casgevy for two ...